Brief: Seelos Therapeutics Doses First Patient In Part 2 Of A Registrational Study Of Sls-002 In Patients With Major Depressive Disorder

Seelos Therapeutics

06/07/2021 13:05

July 6 (Reuters) - Seelos Therapeutics Inc  SEEL.O :
    * SEELOS THERAPEUTICS DOSES FIRST PATIENT IN PART 2 OF A
REGISTRATIONAL STUDY OF SLS-002 (INTRANASAL RACEMIC KETAMINE)
FOR ACUTE SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH MAJOR
DEPRESSIVE DISORDER

Source text for Eikon:  ID:nPnpT5kMa 
Further company coverage:  SEEL.O 

 ((Reuters.Briefs@thomsonreuters.com;))